rofecoxib has been researched along with Arthritis, Degenerative in 141 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " This safety study compared the GI tolerability, the blood pressure (BP) profile and the incidence of oedema with lumiracoxib and rofecoxib in the treatment of OA." | 9.13 | A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients. ( Krammer, G; Stricker, K; Yu, S, 2008) |
| "To compare the lower osteoarthritis (OA) dose of rofecoxib to the recommended dose of celecoxib in two identically designed studies." | 9.12 | Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. ( Birbara, C; Chang, DJ; Petruschke, RA; Rodgers, A; Ruoff, G; Sheldon, E; Tershakovec, AM; Valenzuela, C, 2006) |
| "To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)." | 9.11 | Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005) |
| "5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP) as add-on therapy for subjects with osteoarthritis (OA) pain inadequately controlled by COX-2 nonsteroidal antiinflammatory drugs (NSAID)." | 9.11 | Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. ( Emkey, R; Jordan, D; Kamin, M; Rosenthal, N; Wu, SC, 2004) |
| "An open-label multicentre study was conducted in primary care centres in Spain to investigate the effect of a switch from celecoxib to rofecoxib among patients with osteoarthritis and to identify factors associated with a good response to rofecoxib treatment." | 9.10 | Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. ( Collantes-Estevez, E; Fernandez-Perez, C, 2003) |
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 9.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect." | 9.10 | A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003) |
| "To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis." | 9.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| "To compare patient and physician attitudes to osteoarthritis (OA) treatment with rofecoxib or traditional non-steroidal anti-inflammatory drugs (tNSAIDs)." | 9.10 | Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study. ( Aragón, B; Arboleya, LR; de la Figuera, E; Soledad García, M, 2003) |
| " We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor." | 9.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| "1), the rofecoxib group vs the Arthrotec group respectively reported diarrhea 6." | 9.09 | Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. ( Acevedo, E; Beaulieu, AD; Caeiro, F; Casas, N; Castañeda, O; Garza-Elizondo, M; Gutierrez-Ureña, S; Hinojosa, W; Irazoque, F; Laurenzi, M; Pons-Estel, B; Rodgers, DB; Ugaz, M; Vandormael, K, 2001) |
| "Both doses of rofecoxib demonstrated efficacy clinically comparable with ibuprofen as assessed by 3 primary end points (pain walking on a flat surface [Western Ontario and McMaster Universities Osteoarthritis Index], patient global assessment of response to therapy, and investigator global assessment of disease status) according to predefined comparability criteria." | 9.09 | A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. ( Bolognese, J; Castaneda, O; Daniels, B; Day, R; Ehrich, E; Helgetveit, KB; Kress, B; Krupa, D; Luza, A; Morrison, B; Nahir, M; Seidenberg, B; Strusberg, A, 2000) |
| "This 6-week study was conducted to test the efficacy, safety, and tolerability of rofecoxib (a selective COX-2 inhibitor) compared to nabumetone (a non-selective NSAID) and placebo in osteoarthritis (OA) patients aged 80 and older." | 9.09 | A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. ( Bolognese, J; DeTora, L; Ehrich, E; Ettinger, WH; Greenwald, M; Sperling, RS; Truitt, KE; Zeng, Q, 2001) |
| "Results of phase III clinical trials of rofecoxib, a selective inhibitor of cyclooxygenase 2, have shown that osteoarthritis patients treated with rofecoxib had significantly fewer clinically significant gastrointestinal (GI) adverse events than those who received nonselective nonsteroidal anti-inflammatory drugs (NSAIDs)." | 8.81 | Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. ( Harper, SE; Kong, SX; Pellissier, JM; Straus, WL; Watson, DJ, 2001) |
| " To test whether COX-2 inhibition with rofecoxib would have greater GI tolerability than nonselective COX-1 and COX-2 inhibition, we compared the incidences of (1) treatment discontinuations for GI adverse events (AEs) and (2) prespecified dyspeptic-type GI AEs among patients with osteoarthritis treated with rofecoxib vs NSAIDs." | 8.80 | Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. ( Bolognese, JA; Harper, SE; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 2000) |
| "The aim of the study was to investigate the effects of the cylooxygenase (COX)-2 specific inhibitor rofecoxib, on blood pressure (BP) and heart rate (HR) in patients with well-controlled hypertension and osteoarthritis via 24-h ambulatory monitoring." | 7.73 | The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis. ( Altok, KR; Arinsoy, T; Aydin, M; Ayerden-Ebinc, F; Derici, U; Erten, Y; Goker, B; Haznedaroglu, S; Sindel, S, 2005) |
| "To investigate the relationship between nonselective nonsteroidal antiinflammatory drugs (NS NSAID), rofecoxib, celecoxib, and risk of edema and blood pressure destabilization in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) receiving ordinary clinic care." | 7.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| " Recently, head-to-head, randomized, controlled trials have shown a significantly higher incidence of blood pressure (BP) destabilization and clinically significant edema with rofecoxib than with celecoxib among older, hypertensive patients with osteoarthritis (OA)." | 7.72 | A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003) |
| "A post-marketing surveillance study was conducted in Germany to assess the efficacy and tolerability of rofecoxib in the treatment of osteoarthritis (OA)." | 7.71 | Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany. ( Schattenkirchner, M; Zacher, J, 2002) |
| "The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12." | 7.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 7.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 7.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "To evaluate the potential clinical and economic consequences of rofecoxib prescription in Ontario, Canada, for patients with osteoarthritis (OA) aged >65 years who did not respond to paracetamol (acetaminophen) therapy." | 7.71 | Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. ( Attard, CL; Kong, SX; Marentette, MA; Marshall, JK; Pellissier, JM, 2001) |
| "To evaluate the efficacy of rofecoxib (Vioxx) in subpopulations of patients with osteoarthritis (OA) identified by demographic or baseline disease characteristics, or varied OA involvement." | 7.71 | Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. ( Bolognese, J; Detora, LM; Ehrich, EW; Krupa, D; Sperling, RS, 2001) |
| "A nationwide survey was undertaken among 74,192 patients with osteoarthritis (OA) and 5986 physicians (including 5265 general practitioners [GPs]) in Belgium to evaluate satisfaction with the selective cyclo-oxygenase-2 inhibitor rofecoxib (12." | 7.71 | Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey. ( Poriau, S; Steinfeld, S, 2001) |
| " We report a case of reversible acute renal failure due to acute tubulointerstitial nephritis, confirmed by histology of a renal biopsy sample, associated with taking rofecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor." | 7.71 | Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. ( Fernández-Alonso, J; Rocha, JL, 2001) |
| "Rofecoxib 25 mg was significantly better than celecoxib 200 mg in relieving night pain at 6 weeks in one study; this was not confirmed in the accompanying study." | 6.72 | Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. ( Polis, AB; Rubin, BR; Schnitzer, TJ; Smugar, SS; Tershakovec, AM; Weaver, AL, 2006) |
| "Rofecoxib treatment increased physical and mental HRQL domain scores on the SF-36." | 6.70 | Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. ( Bolognese, JA; Ehrich, EW; Kong, SX; Watson, DJ, 2001) |
| "Rofecoxib was voluntarily withdrawn from global markets in October 2004 therefore there are no implications for practice concerning its use." | 6.43 | Rofecoxib for osteoarthritis. ( Fidan, DD; Frankish, R; Garner, SE; Maxwell, L, 2005) |
| "Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day." | 6.41 | Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. ( Figgitt, DP; Matheson, AJ, 2001) |
| "Rofecoxib withdrawal has markedly changed the prescribing pattern of drugs that are used in OA-related pain treatment, with a striking decrease of coxib use in Italian general practice." | 5.35 | Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. ( Alacqua, M; Arcoraci, V; Caporali, R; Caputi, AP; Cavagna, L; Galdo, M; Montecucco, CM; Moretti, S; Tari, DU; Trifirò, G, 2008) |
| "Celecoxib was dominated by diclofenac in average-risk patients." | 5.32 | The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003) |
| "Rofecoxib is a nonsteroidal anti-inflammatory drug that is reported to act by selectively inhibiting cyclooxygenase-2." | 5.31 | Aseptic meningitis associated with rofecoxib. ( Beitz, J; Bonnel, RA; Karwoski, CB; Villalba, ML, 2002) |
| " This safety study compared the GI tolerability, the blood pressure (BP) profile and the incidence of oedema with lumiracoxib and rofecoxib in the treatment of OA." | 5.13 | A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients. ( Krammer, G; Stricker, K; Yu, S, 2008) |
| "To compare the lower osteoarthritis (OA) dose of rofecoxib to the recommended dose of celecoxib in two identically designed studies." | 5.12 | Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. ( Birbara, C; Chang, DJ; Petruschke, RA; Rodgers, A; Ruoff, G; Sheldon, E; Tershakovec, AM; Valenzuela, C, 2006) |
| "5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP) as add-on therapy for subjects with osteoarthritis (OA) pain inadequately controlled by COX-2 nonsteroidal antiinflammatory drugs (NSAID)." | 5.11 | Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. ( Emkey, R; Jordan, D; Kamin, M; Rosenthal, N; Wu, SC, 2004) |
| "Osteoarthritis patients > or =50 years of age without ulcers or erosive esophagitis at baseline endoscopy were assigned randomly to placebo, enteric-coated aspirin 81 mg/day, rofecoxib 25 mg combined with aspirin 81 mg/day, or ibuprofen 800 mg 3 times a day." | 5.11 | Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. ( Laine, L; Maller, ES; Quan, H; Simon, T; Yu, C, 2004) |
| "5), with symptomatic osteoarthritis of hip or knee were included in an open label study with rofecoxib." | 5.11 | Responsiveness of the electronic touch screen WOMAC 3.1 OA Index in a short term clinical trial with rofecoxib. ( Bellamy, N; Bischoff-Ferrari, HA; Good, M; Theiler, R, 2004) |
| " Therefore, we conducted a double-blind, randomized trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-hour blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis." | 5.11 | The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. ( Brabant, T; Fort, JG; Kivitz, A; Pitt, B; Simon, LS; Sowers, JR; van Ingen, H; Whelton, A; White, WB; Winer, N, 2005) |
| "To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)." | 5.11 | Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005) |
| "To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis." | 5.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| "Patient overall pain assessment, and patient and investigator global assessments were each measured on a 100mm VAS and on a 0 to 4 point Likert scale in a 6-week OA study of rofecoxib vs placebo." | 5.10 | Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. ( Bolognese, JA; Ehrich, EW; Schnitzer, TJ, 2003) |
| "To compare patient and physician attitudes to osteoarthritis (OA) treatment with rofecoxib or traditional non-steroidal anti-inflammatory drugs (tNSAIDs)." | 5.10 | Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study. ( Aragón, B; Arboleya, LR; de la Figuera, E; Soledad García, M, 2003) |
| "The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect." | 5.10 | A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003) |
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 5.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "To compare the efficacy of the cyclooxygenase 2 (COX-2)-specific inhibitors celecoxib and rofecoxib in treating the signs and symptoms of osteoarthritis (OA)." | 5.10 | Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. ( Fort, JG; Gibofsky, A; McKenna, F; Williams, GW, 2003) |
| "An open-label multicentre study was conducted in primary care centres in Spain to investigate the effect of a switch from celecoxib to rofecoxib among patients with osteoarthritis and to identify factors associated with a good response to rofecoxib treatment." | 5.10 | Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. ( Collantes-Estevez, E; Fernandez-Perez, C, 2003) |
| " We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor." | 5.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| "Both doses of rofecoxib demonstrated efficacy clinically comparable with ibuprofen as assessed by 3 primary end points (pain walking on a flat surface [Western Ontario and McMaster Universities Osteoarthritis Index], patient global assessment of response to therapy, and investigator global assessment of disease status) according to predefined comparability criteria." | 5.09 | A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. ( Bolognese, J; Castaneda, O; Daniels, B; Day, R; Ehrich, E; Helgetveit, KB; Kress, B; Krupa, D; Luza, A; Morrison, B; Nahir, M; Seidenberg, B; Strusberg, A, 2000) |
| "In healthy subjects, treatment with rofecoxib, at 2 to 4 times the doses that are currently recommended for the treatment of patients with osteoarthritis, produced significantly less fecal blood loss than a therapeutic dose of ibuprofen and was equivalent to placebo." | 5.09 | A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. ( Bolognese, JA; Bowen, B; Cagliola, A; Hunt, RH; James, C; Mortensen, ER; Quan, H; Simon, TJ, 2000) |
| "1), the rofecoxib group vs the Arthrotec group respectively reported diarrhea 6." | 5.09 | Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. ( Acevedo, E; Beaulieu, AD; Caeiro, F; Casas, N; Castañeda, O; Garza-Elizondo, M; Gutierrez-Ureña, S; Hinojosa, W; Irazoque, F; Laurenzi, M; Pons-Estel, B; Rodgers, DB; Ugaz, M; Vandormael, K, 2001) |
| "This 6-week study was conducted to test the efficacy, safety, and tolerability of rofecoxib (a selective COX-2 inhibitor) compared to nabumetone (a non-selective NSAID) and placebo in osteoarthritis (OA) patients aged 80 and older." | 5.09 | A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. ( Bolognese, J; DeTora, L; Ehrich, E; Ettinger, WH; Greenwald, M; Sperling, RS; Truitt, KE; Zeng, Q, 2001) |
| "We analysed pooled data from two identical double-blind, randomized, 12-week endoscopy studies which compared the gastroduodenal toxicity of placebo (n=371), rofecoxib 25 mg (n=390), rofecoxib 50 mg (n=379), and ibuprofen 2400 mg daily (n=376) in patients with osteoarthritis." | 5.09 | Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. ( Bolognese, JA; Harper, SE; Hawkey, CJ; Laine, L; Mortensen, E; Quan, HU, 2001) |
| " Some, but not all, studies have suggested increased myocardial infarction with certain cyclooxygenase-2 inhibitors, in particular rofecoxib." | 4.82 | Cyclooxygenase-2 inhibitors. ( Fortun, PJ; Hawkey, CJ, 2005) |
| "Although the published literature is limited, the data indicate that rofecoxib is an effective analgesic agent for the painful conditions in which it has been studied." | 4.81 | Rofecoxib: clinical pharmacology and clinical experience. ( Weaver, AL, 2001) |
| "Results of phase III clinical trials of rofecoxib, a selective inhibitor of cyclooxygenase 2, have shown that osteoarthritis patients treated with rofecoxib had significantly fewer clinically significant gastrointestinal (GI) adverse events than those who received nonselective nonsteroidal anti-inflammatory drugs (NSAIDs)." | 4.81 | Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. ( Harper, SE; Kong, SX; Pellissier, JM; Straus, WL; Watson, DJ, 2001) |
| " To test whether COX-2 inhibition with rofecoxib would have greater GI tolerability than nonselective COX-1 and COX-2 inhibition, we compared the incidences of (1) treatment discontinuations for GI adverse events (AEs) and (2) prespecified dyspeptic-type GI AEs among patients with osteoarthritis treated with rofecoxib vs NSAIDs." | 4.80 | Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. ( Bolognese, JA; Harper, SE; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 2000) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| "The aim of the study was to investigate the effects of the cylooxygenase (COX)-2 specific inhibitor rofecoxib, on blood pressure (BP) and heart rate (HR) in patients with well-controlled hypertension and osteoarthritis via 24-h ambulatory monitoring." | 3.73 | The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis. ( Altok, KR; Arinsoy, T; Aydin, M; Ayerden-Ebinc, F; Derici, U; Erten, Y; Goker, B; Haznedaroglu, S; Sindel, S, 2005) |
| " This study evaluated average daily doses and costs of rofecoxib and celecoxib and concomitant use of gastroprotective agents (GPAs) in elderly patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in Quebec, prior to the rofecoxib withdrawal." | 3.73 | Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? ( Chabot, I; Hunsche, E; Rahme, E; Toubouti, Y, 2006) |
| "This study assessed prescribing patterns for rofecoxib and celecoxib in the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as differences in prescribing patterns across physician specialties." | 3.72 | An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. ( Kong, SX; Mavros, P; Mitchell, JH; Pellissier, JM; Schnitzer, TJ; Straus, WL; Watson, DJ, 2003) |
| " Recently, head-to-head, randomized, controlled trials have shown a significantly higher incidence of blood pressure (BP) destabilization and clinically significant edema with rofecoxib than with celecoxib among older, hypertensive patients with osteoarthritis (OA)." | 3.72 | A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003) |
| "A total of 3639 patients with rheumatoid arthritis (RA), osteoarthritis, and fibromyalgia starting therapy of celecoxib, rofecoxib, naproxen, or ibuprofen were surveyed at 6-month intervals for up to 2." | 3.72 | Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. ( Burke, TA; Michaud, K; Wolfe, F; Zhao, SZ, 2004) |
| "To investigate the relationship between nonselective nonsteroidal antiinflammatory drugs (NS NSAID), rofecoxib, celecoxib, and risk of edema and blood pressure destabilization in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) receiving ordinary clinic care." | 3.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| "To evaluate the potential clinical and economic consequences of rofecoxib prescription in Ontario, Canada, for patients with osteoarthritis (OA) aged >65 years who did not respond to paracetamol (acetaminophen) therapy." | 3.71 | Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. ( Attard, CL; Kong, SX; Marentette, MA; Marshall, JK; Pellissier, JM, 2001) |
| "The aim of this study was to describe physician-reported management of clinically significant edema and/or destabilized blood pressure in patients with osteoarthritis (OA) and hypertension when initiating therapy with rofecoxib or celecoxib." | 3.71 | Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. ( Bristol, S; Burke, TA; May, C; Osterhaus, JT; Wentworth, C; Whelton, A, 2002) |
| "A post-marketing surveillance study was conducted in Germany to assess the efficacy and tolerability of rofecoxib in the treatment of osteoarthritis (OA)." | 3.71 | Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany. ( Schattenkirchner, M; Zacher, J, 2002) |
| "To evaluate the efficacy of rofecoxib (Vioxx) in subpopulations of patients with osteoarthritis (OA) identified by demographic or baseline disease characteristics, or varied OA involvement." | 3.71 | Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. ( Bolognese, J; Detora, LM; Ehrich, EW; Krupa, D; Sperling, RS, 2001) |
| " We report a case of reversible acute renal failure due to acute tubulointerstitial nephritis, confirmed by histology of a renal biopsy sample, associated with taking rofecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor." | 3.71 | Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. ( Fernández-Alonso, J; Rocha, JL, 2001) |
| "A nationwide survey was undertaken among 74,192 patients with osteoarthritis (OA) and 5986 physicians (including 5265 general practitioners [GPs]) in Belgium to evaluate satisfaction with the selective cyclo-oxygenase-2 inhibitor rofecoxib (12." | 3.71 | Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey. ( Poriau, S; Steinfeld, S, 2001) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 3.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "To report a case of a paresthesia-type reaction due to the use of rofecoxib in standard doses for the treatment of osteoarthritis." | 3.71 | Idiopathic paresthesia reaction associated with rofecoxib. ( Daugherty, KK; Gora-Harper, ML, 2002) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 3.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12." | 3.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| "A population of 6637 patients with rheumatoid arthritis (RA) and osteoarthritis (OA) from the practices of 433 US rheumatologists completed 2 sets of detailed questionnaires concerning (1) the last 6 months in 1998 and (2) the first 6 months of 1999, generally prior to and after the release of celecoxib and rofecoxib." | 3.71 | Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr ( Arguelles, LM; Burke, TA; Flowers, N; Pettitt, D; Wolfe, F, 2002) |
| "Rofecoxib caused an increase in BP compared to celecoxib; a change in recumbent systolic BP +/- SD (6." | 2.72 | Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels? ( Aw, TJ; Billah, B; Krum, H; Liew, D; Morel-Kopp, MC; Schneider, HG; Tofler, GH, 2006) |
| "Rofecoxib 25 mg was significantly better than celecoxib 200 mg in relieving night pain at 6 weeks in one study; this was not confirmed in the accompanying study." | 2.72 | Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. ( Polis, AB; Rubin, BR; Schnitzer, TJ; Smugar, SS; Tershakovec, AM; Weaver, AL, 2006) |
| "Rofecoxib treatment increased physical and mental HRQL domain scores on the SF-36." | 2.70 | Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. ( Bolognese, JA; Ehrich, EW; Kong, SX; Watson, DJ, 2001) |
| " Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with COX-2 inhibitors in patients with OA were eligible for inclusion." | 2.61 | Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. ( Baird, J; Bruyère, O; Cooper, C; Corp, N; Curtis, E; Dennison, E; Fuggle, N; Honvo, G; Maggi, S; Ntani, G; Parsons, C; Reginster, JY; Shaw, S; Spooner, L, 2019) |
| "Rofecoxib was voluntarily withdrawn from global markets in October 2004 therefore there are no implications for practice concerning its use." | 2.43 | Rofecoxib for osteoarthritis. ( Fidan, DD; Frankish, R; Garner, SE; Maxwell, L, 2005) |
| " In the VIGOR gastrointestinal outcomes trial of >8000 patients, naproxen (an NSAID with aspirin-like sustained antiplatelet effects throughout its dosing interval) was associated with a significantly lower risk of CV events than was rofecoxib." | 2.42 | Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. ( Gertz, BJ; Reicin, A; Sperling, RS; Weir, MR, 2003) |
| " Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone)." | 2.41 | Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. ( Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR, 2001) |
| "Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day." | 2.41 | Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. ( Figgitt, DP; Matheson, AJ, 2001) |
| "In the second patient, acute renal failure necessitated hemodialysis." | 2.41 | Nephrotoxicity of selective COX-2 inhibitors. ( Haller, H; Köhler, L; Mengel, M; Schwarz, A; Woywodt, A; Zeidler, H, 2001) |
| " During repeated dosage with the specific COX-2 inhibitors, the 24 hour urinary excretion of sodium is only inhibited for the first day of treatment while the excretion of sodium is still decreased over the first 3 hours after the individual doses." | 2.41 | Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). ( Day, RO; Graham, GG; Graham, RI, 2002) |
| "Celecoxib and rofecoxib have been used in Norway since 2000." | 2.41 | [A critical evaluation of side effect data on COX-2 inhibitors]. ( Pomp, E, 2002) |
| " However, NSAIDs cause significant adverse upper gastrointestinal effects, including increased mortality from serious ulcer complications." | 2.41 | Selective inhibitors of COX-2--are they safe for the stomach? ( Giercksky, KE; Haglund, U; Rask-Madsen, J, 2000) |
| " The initial oral dosage of rofecoxib is 12." | 2.41 | [Pharma-clinics. The drug of the month. Rofecoxib (Vioxx)]. ( Scheen, AJ, 2000) |
| " Compound 22 exhibited good pharmacokinetic properties and excellent oral bioavailability (F=78%, rat)." | 1.39 | Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy. ( Banotai, C; Baum, H; Beidler, D; Bove, S; Braden, T; Cornicelli, J; Goodman, A; Gowan, R; Hicks, J; Lightle, S; Lu, XK; Miller, H; Ogden, A; Pandit, J; Plummer, MS; Roark, H; Sadagopan, N; Sanchez, B; Sarver, R; Shahripour, A; Shen, XQ; Skalitzky, DJ; Spessard, C; Stankovic, CJ; Welch, K; Whitehead, C, 2013) |
| "Rofecoxib withdrawal has markedly changed the prescribing pattern of drugs that are used in OA-related pain treatment, with a striking decrease of coxib use in Italian general practice." | 1.35 | Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. ( Alacqua, M; Arcoraci, V; Caporali, R; Caputi, AP; Cavagna, L; Galdo, M; Montecucco, CM; Moretti, S; Tari, DU; Trifirò, G, 2008) |
| "When rofecoxib was withdrawn in 2004, paracetamol should have been offered as replacement." | 1.35 | Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market. ( Barozzi, N; Tett, SE, 2009) |
| "Celecoxib and naproxen were not associated with increased risks." | 1.35 | Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. ( Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J, 2008) |
| "Among 7." | 1.33 | Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? ( Coupal, L; Grover, SA; Zowall, H, 2005) |
| "We evaluated their use in the treatment of osteoarthritis by general practitioners, with special attention to concomitant prescription of gastroprotective agents." | 1.32 | Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. ( Bouée, S; Charlemagne, A; Fagnani, F; Lancry, PJ; Le Jeunne, P; Naudin, F; Sermet, C, 2004) |
| "Rofecoxib users were at a significantly increased relative risk of new onset hypertension compared with patients taking celecoxib (odds ratio [OR] 1." | 1.32 | Relationship between COX-2 specific inhibitors and hypertension. ( Avorn, J; Levin, R; Schneeweiss, S; Solomon, DH, 2004) |
| "Celecoxib was dominated by diclofenac in average-risk patients." | 1.32 | The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003) |
| "Osteoarthritis was the most common indication (68." | 1.31 | A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. ( Cutts, C; LaCaze, A; Tett, S, 2002) |
| "Rofecoxib is a nonsteroidal anti-inflammatory drug that is reported to act by selectively inhibiting cyclooxygenase-2." | 1.31 | Aseptic meningitis associated with rofecoxib. ( Beitz, J; Bonnel, RA; Karwoski, CB; Villalba, ML, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (5.67) | 18.2507 |
| 2000's | 131 (92.91) | 29.6817 |
| 2010's | 2 (1.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Plummer, MS | 1 |
| Cornicelli, J | 1 |
| Roark, H | 1 |
| Skalitzky, DJ | 1 |
| Stankovic, CJ | 1 |
| Bove, S | 1 |
| Pandit, J | 1 |
| Goodman, A | 1 |
| Hicks, J | 1 |
| Shahripour, A | 1 |
| Beidler, D | 1 |
| Lu, XK | 1 |
| Sanchez, B | 1 |
| Whitehead, C | 1 |
| Sarver, R | 1 |
| Braden, T | 1 |
| Gowan, R | 1 |
| Shen, XQ | 1 |
| Welch, K | 1 |
| Ogden, A | 1 |
| Sadagopan, N | 1 |
| Baum, H | 1 |
| Miller, H | 1 |
| Banotai, C | 1 |
| Spessard, C | 1 |
| Lightle, S | 1 |
| Curtis, E | 1 |
| Fuggle, N | 1 |
| Shaw, S | 1 |
| Spooner, L | 1 |
| Ntani, G | 1 |
| Parsons, C | 1 |
| Corp, N | 1 |
| Honvo, G | 1 |
| Baird, J | 1 |
| Maggi, S | 1 |
| Dennison, E | 1 |
| Bruyère, O | 1 |
| Reginster, JY | 1 |
| Cooper, C | 1 |
| Stricker, K | 1 |
| Yu, S | 1 |
| Krammer, G | 1 |
| Barozzi, N | 1 |
| Tett, SE | 1 |
| Osterhaus, JT | 1 |
| Burke, TA | 6 |
| May, C | 1 |
| Wentworth, C | 2 |
| Whelton, A | 4 |
| Bristol, S | 1 |
| Wooltorton, E | 1 |
| Steinfeld, S | 2 |
| Bjørke, PA | 1 |
| Zacher, J | 1 |
| Schattenkirchner, M | 1 |
| White, WB | 3 |
| Bello, AE | 2 |
| Puma, JA | 1 |
| Fort, JG | 4 |
| Zhao, SZ | 3 |
| von Allmen, H | 1 |
| Henderson, SC | 1 |
| Mamdani, M | 1 |
| Rochon, P | 1 |
| Laupacis, A | 1 |
| Anderson, G | 1 |
| Cutts, C | 1 |
| LaCaze, A | 1 |
| Tett, S | 1 |
| Hochberg, MC | 2 |
| Hutchins, V | 1 |
| Hutchins, B | 1 |
| Bannwarth, B | 1 |
| Ravaud, P | 1 |
| Dougados, M | 1 |
| Harley, C | 1 |
| Wagner, S | 1 |
| Lehmann, FS | 1 |
| Gyr, N | 1 |
| Russo, P | 1 |
| Capone, A | 1 |
| Attanasio, E | 1 |
| Baio, G | 1 |
| Di Martino, M | 1 |
| Degli Esposti, L | 1 |
| Marchetta, F | 1 |
| Buda, S | 1 |
| Degli Esposti, E | 1 |
| Caprino, L | 1 |
| Weaver, A | 1 |
| Alderman, M | 1 |
| Sperling, R | 1 |
| Becker, RV | 1 |
| McCoy, MA | 1 |
| Trotter, JP | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Maetzel, A | 1 |
| Krahn, M | 1 |
| Naglie, G | 1 |
| Bolognese, JA | 10 |
| Schnitzer, TJ | 4 |
| Ehrich, EW | 5 |
| Layton, D | 1 |
| Heeley, E | 1 |
| Hughes, K | 1 |
| Shakir, SA | 1 |
| Arboleya, LR | 1 |
| de la Figuera, E | 1 |
| Soledad García, M | 1 |
| Aragón, B | 1 |
| Chiolero, A | 1 |
| Maillard, MP | 1 |
| Burnier, M | 1 |
| Collantes-Estevez, E | 1 |
| Fernandez-Perez, C | 1 |
| Bianchi, M | 1 |
| Broggini, M | 1 |
| Lisse, JR | 1 |
| Perlman, M | 1 |
| Johansson, G | 1 |
| Shoemaker, JR | 1 |
| Schechtman, J | 1 |
| Skalky, CS | 1 |
| Dixon, ME | 1 |
| Polis, AB | 2 |
| Mollen, AJ | 1 |
| Geba, GP | 1 |
| Weir, MR | 2 |
| Sperling, RS | 6 |
| Reicin, A | 3 |
| Gertz, BJ | 3 |
| Oviedo, JA | 1 |
| Wolfe, MM | 1 |
| Gibofsky, A | 1 |
| Williams, GW | 1 |
| McKenna, F | 1 |
| Burian, M | 1 |
| Geisslinger, G | 2 |
| Emkey, R | 1 |
| Rosenthal, N | 1 |
| Wu, SC | 1 |
| Jordan, D | 1 |
| Kamin, M | 1 |
| Kong, SX | 4 |
| Mitchell, JH | 1 |
| Mavros, P | 1 |
| Watson, DJ | 7 |
| Pellissier, JM | 3 |
| Straus, WL | 2 |
| Schmidt, H | 1 |
| Woodcock, BG | 1 |
| Wolfe, F | 3 |
| Michaud, K | 1 |
| Makuch, RW | 1 |
| Ashton, D | 1 |
| Kim, P | 1 |
| Griffiths, N | 1 |
| Beran, R | 1 |
| Zhao, S | 1 |
| Pettitt, D | 2 |
| Bouée, S | 1 |
| Charlemagne, A | 1 |
| Fagnani, F | 1 |
| Le Jeunne, P | 1 |
| Sermet, C | 1 |
| Naudin, F | 1 |
| Lancry, PJ | 1 |
| Hanauer, LB | 1 |
| Jenkinson, ML | 1 |
| Rusche, JM | 1 |
| Solomon, DH | 1 |
| Schneeweiss, S | 1 |
| Levin, R | 1 |
| Avorn, J | 1 |
| Tran, F | 1 |
| Boggie, DT | 1 |
| Delattre, ML | 1 |
| Schaefer, MG | 1 |
| Morreale, AP | 1 |
| Plowman, BK | 1 |
| Laine, L | 3 |
| Maller, ES | 1 |
| Yu, C | 1 |
| Quan, H | 5 |
| Simon, T | 2 |
| Ariza-Ariza, R | 1 |
| Hernández-Cruz, B | 1 |
| Navarro-Sarabia, F | 1 |
| Theiler, R | 1 |
| Bischoff-Ferrari, HA | 1 |
| Good, M | 1 |
| Bellamy, N | 2 |
| Hedner, T | 1 |
| Himmelmann, A | 1 |
| Grover, SA | 1 |
| Coupal, L | 1 |
| Zowall, H | 1 |
| Simon, LS | 2 |
| Strand, V | 1 |
| Yodfat, Y | 1 |
| Goldstein, JL | 1 |
| Spalding, W | 1 |
| Suh, S | 1 |
| Nelson, M | 1 |
| Cicuttini, F | 1 |
| Garner, SE | 1 |
| Fidan, DD | 1 |
| Frankish, R | 1 |
| Maxwell, L | 1 |
| Sowers, JR | 1 |
| Pitt, B | 1 |
| Winer, N | 1 |
| Kivitz, A | 1 |
| van Ingen, H | 1 |
| Brabant, T | 1 |
| Giannitsis, E | 1 |
| Florentinus, SR | 1 |
| Nielsen, MW | 1 |
| van Dijk, L | 1 |
| Leufkens, HG | 1 |
| Hansen, EH | 1 |
| Heerdink, ER | 1 |
| Hegmann, T | 1 |
| Lee, A | 1 |
| Braunstein, N | 1 |
| Polis, A | 1 |
| Derici, U | 1 |
| Goker, B | 1 |
| Ayerden-Ebinc, F | 1 |
| Altok, KR | 1 |
| Erten, Y | 1 |
| Haznedaroglu, S | 1 |
| Aydin, M | 1 |
| Arinsoy, T | 1 |
| Sindel, S | 1 |
| Hawkey, CJ | 3 |
| Fortun, PJ | 1 |
| Birbara, C | 1 |
| Ruoff, G | 1 |
| Sheldon, E | 1 |
| Valenzuela, C | 1 |
| Rodgers, A | 1 |
| Petruschke, RA | 1 |
| Chang, DJ | 1 |
| Tershakovec, AM | 2 |
| Rahme, E | 1 |
| Hunsche, E | 1 |
| Toubouti, Y | 1 |
| Chabot, I | 1 |
| Tannenbaum, H | 1 |
| Smugar, SS | 1 |
| Weaver, AL | 2 |
| Rubin, BR | 1 |
| Aw, TJ | 1 |
| Liew, D | 1 |
| Tofler, GH | 1 |
| Schneider, HG | 1 |
| Morel-Kopp, MC | 1 |
| Billah, B | 1 |
| Krum, H | 1 |
| Sato, K | 1 |
| Yamada, E | 1 |
| Uehara, Y | 1 |
| Takagi, H | 1 |
| Mori, M | 1 |
| Ashworth, AJ | 1 |
| Singh, H | 1 |
| Wendt, JA | 1 |
| Deeter, SD | 1 |
| Bove, SE | 1 |
| Knauer, CS | 1 |
| Brooker, RM | 1 |
| Augelli-Szafran, CE | 1 |
| Schwarz, RD | 1 |
| Kinsora, JJ | 1 |
| Kilgore, KS | 1 |
| Wall, R | 1 |
| Strickland, C | 1 |
| Jamieson, B | 1 |
| Lo, V | 1 |
| Alacqua, M | 1 |
| Trifirò, G | 1 |
| Cavagna, L | 1 |
| Caporali, R | 1 |
| Montecucco, CM | 1 |
| Moretti, S | 1 |
| Tari, DU | 1 |
| Galdo, M | 1 |
| Caputi, AP | 1 |
| Arcoraci, V | 1 |
| Cunnington, M | 1 |
| Webb, D | 1 |
| Qizilbash, N | 1 |
| Blum, D | 1 |
| Mander, A | 1 |
| Funk, MJ | 1 |
| Weil, J | 1 |
| Seidenberg, BC | 2 |
| Scott, LJ | 1 |
| Lamb, HM | 1 |
| Harper, S | 1 |
| Bath, R | 1 |
| Johanson, J | 1 |
| Schwartz, H | 1 |
| Stern, S | 1 |
| Bolognese, J | 4 |
| Langman, MJ | 1 |
| Jensen, DM | 1 |
| Harper, SE | 6 |
| Zhao, PL | 3 |
| Simon, TJ | 5 |
| Miller, JL | 1 |
| Blondon, H | 1 |
| Strassels, S | 1 |
| Day, R | 1 |
| Morrison, B | 1 |
| Luza, A | 1 |
| Castaneda, O | 2 |
| Strusberg, A | 1 |
| Nahir, M | 1 |
| Helgetveit, KB | 1 |
| Kress, B | 1 |
| Daniels, B | 1 |
| Krupa, D | 3 |
| Seidenberg, B | 1 |
| Ehrich, E | 2 |
| Oliw, E | 1 |
| Wollheim, FA | 1 |
| Hunt, RH | 1 |
| Bowen, B | 1 |
| Mortensen, ER | 1 |
| James, C | 1 |
| Cagliola, A | 1 |
| Scheen, AJ | 1 |
| Brooks, PM | 1 |
| Day, RO | 2 |
| Davies, GM | 1 |
| Jackson, L | 1 |
| Mortensen, E | 2 |
| Lines, CR | 1 |
| Giercksky, KE | 1 |
| Haglund, U | 1 |
| Rask-Madsen, J | 1 |
| Cannon, GW | 1 |
| Breedveld, FC | 1 |
| Acevedo, E | 1 |
| Ugaz, M | 1 |
| Beaulieu, AD | 1 |
| Pons-Estel, B | 1 |
| Caeiro, F | 1 |
| Casas, N | 1 |
| Garza-Elizondo, M | 1 |
| Irazoque, F | 1 |
| Hinojosa, W | 1 |
| Gutierrez-Ureña, S | 1 |
| Vandormael, K | 1 |
| Rodgers, DB | 1 |
| Laurenzi, M | 1 |
| Pasero, C | 1 |
| McCaffery, M | 1 |
| Caroli, A | 1 |
| Monica, F | 1 |
| Matheson, AJ | 1 |
| Figgitt, DP | 1 |
| Truitt, KE | 1 |
| Ettinger, WH | 1 |
| Greenwald, M | 1 |
| DeTora, L | 1 |
| Zeng, Q | 1 |
| Rocha, JL | 1 |
| Fernández-Alonso, J | 1 |
| Wildy, KS | 1 |
| Wasko, MC | 1 |
| Adler, J | 1 |
| Woywodt, A | 1 |
| Schwarz, A | 1 |
| Mengel, M | 1 |
| Haller, H | 1 |
| Zeidler, H | 1 |
| Köhler, L | 1 |
| Quan, HU | 1 |
| Konstam, MA | 1 |
| Shapiro, D | 2 |
| Barr, E | 2 |
| Detora, LM | 1 |
| Marshall, JK | 1 |
| Attard, CL | 1 |
| Marentette, MA | 1 |
| Schellenberg, RR | 1 |
| Isserow, SH | 1 |
| Poriau, S | 1 |
| Schoenfeld, P | 1 |
| Reicin, AS | 1 |
| Yu, Q | 1 |
| Daugherty, KK | 1 |
| Gora-Harper, ML | 1 |
| Bonnel, RA | 1 |
| Villalba, ML | 1 |
| Karwoski, CB | 1 |
| Beitz, J | 1 |
| Bierma-Zeinstra, SM | 1 |
| Bohnen, AM | 1 |
| Berger, MY | 1 |
| Thomas, S | 1 |
| Henderson, P | 1 |
| Graham, GG | 1 |
| Graham, RI | 1 |
| Pomp, E | 1 |
| Crofford, LJ | 2 |
| Flowers, N | 1 |
| Arguelles, LM | 1 |
| Silas, S | 1 |
| Clegg, DO | 1 |
| Reitblat, T | 1 |
| Zamir, D | 1 |
| Estis, L | 1 |
| Priluk, R | 1 |
| Drogenikov, T | 1 |
| Viskoper, JR | 1 |
| Gupta, S | 1 |
| Harris, ED | 1 |
| Shaughnessy, AF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6-Week Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Parallel Group Clinical Saftey Study to Evaluate Incidence of Predefined Gastrointestinal Adverse Events and Peripheral Edema in Subjects With Primary Osteoarthritis Treated W[NCT00637949] | Phase 3 | 309 participants (Actual) | Interventional | 2000-12-31 | Completed | ||
| Efficiency And Quality In Post-Surgical Pain Therapy After Discharge[NCT05221866] | 711 participants (Actual) | Interventional | 2022-03-14 | Completed | |||
| UControlPain App (This is the Official IRB Title)[NCT03833648] | 60 participants (Actual) | Interventional | 2019-06-19 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee[NCT00092365] | Phase 3 | 413 participants (Actual) | Interventional | 2003-04-01 | Completed | ||
| A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee[NCT00092352] | Phase 3 | 395 participants (Actual) | Interventional | 2003-04-29 | Completed | ||
| Efficacy Evaluation of Intra-articular Hyaluronic Acid (Sinovial®) vs Synvisc® in the Treatment of Symptomatic Knee Osteoarthritis. A Double-blind, Controlled, Randomised, Parallel-group Non-inferiority Study[NCT00556608] | Phase 4 | 381 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Randomized Control Trial Comparing Short-term Outcomes After Direct Anterior and SuperPATH Approaches[NCT03746925] | 100 participants (Anticipated) | Interventional | 2019-09-07 | Recruiting | |||
| The Effects of Bariatric Surgery Weight Loss on Knee Pain in Patients With Osteoarthritis of the Knee[NCT00752765] | 30 participants (Anticipated) | Observational | 2008-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
34 reviews available for rofecoxib and Arthritis, Degenerative
| Article | Year |
|---|---|
Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
Topics: Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Lactones; Oste | 2019 |
Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
Topics: Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibito | 2002 |
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin | 2003 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Ce | 2002 |
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Blood | 2003 |
Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase Inhibitors; Di | 2003 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis | 2003 |
Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis.
Topics: Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Lacto | 2004 |
[Is there a future for COX-2 inhibitors?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 I | 2004 |
Rofecoxib for osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Approval; Humans; Lactones; | 2005 |
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; Cardio | 2005 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cy | 2005 |
Cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Myo | 2005 |
Clinical inquiries. Do COX-2 inhibitors worsen renal function?
Topics: Arthritis, Rheumatoid; Celecoxib; Contraindications; Cyclooxygenase 2 Inhibitors; Humans; Kidney; La | 2007 |
Rofecoxib.
Topics: Analgesics; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Interactions; Dysmenorrhea; En | 1999 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
[New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trial | 2000 |
[Pharma-clinics. The drug of the month. Rofecoxib (Vioxx)].
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biologi | 2000 |
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Clinical Tr | 2000 |
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2001 |
Selective inhibitors of COX-2--are they safe for the stomach?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
Efficacy of cyclooxygenase-2-specific inhibitors.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyge | 2001 |
Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tri | 2001 |
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumat | 2001 |
Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Costs and Cost Analysis; Cyclooxygenase Inhibi | 2001 |
Nephrotoxicity of selective COX-2 inhibitors.
Topics: Acute Kidney Injury; Adult; Arthritis, Psoriatic; Cyclooxygenase Inhibitors; Follow-Up Studies; Huma | 2001 |
Rofecoxib: clinical pharmacology and clinical experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Lactones; Osteoarthritis; Pa | 2001 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2001 |
An evidence-based approach to the gastrointestinal safety profile of COX-2-selective anti-inflammatories.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloo | 2001 |
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
Topics: Acetaminophen; Analgesia; Cardiovascular System; Celecoxib; Clinical Trials as Topic; Cyclooxygenase | 2002 |
[A critical evaluation of side effect data on COX-2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?
Topics: Arthritis; Aspirin; Cardiovascular System; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2002 |
An update on specific COX-2 inhibitors: the COXIBs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2001 |
28 trials available for rofecoxib and Arthritis, Degenerative
| Article | Year |
|---|---|
A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
Topics: Aged; Arthralgia; Blood Pressure; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationshi | 2008 |
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; | 2002 |
Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib.
Topics: Aged; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Isoe | 2003 |
Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Endpoint Determination; Humans; Lacton | 2003 |
Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dyspeps | 2003 |
Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Female; Health Status; Humans; Lactones; Logistic Models | 2003 |
A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.
Topics: Adult; Aged; Analysis of Variance; Celecoxib; Double-Blind Method; Female; Humans; Knee; Lactones; M | 2003 |
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Lactones; Male; Middle Ag | 2003 |
Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; | 2004 |
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxyge | 2004 |
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor | 2004 |
Responsiveness of the electronic touch screen WOMAC 3.1 OA Index in a short term clinical trial with rofecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Computer Terminals; Female; Hip Joint; Humans; Knee J | 2004 |
Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Topics: Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method | 2005 |
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blood Pressure Determi | 2005 |
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Lactones; Male; Middle Ag | 2006 |
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Lactones; Male; Middle Ag | 2006 |
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Lactones; Male; Middle Ag | 2006 |
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Lactones; Male; Middle Ag | 2006 |
Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Double-Blind Method; Female; Humans; Lactones; Male; Midd | 2006 |
Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?
Topics: Aged; Aldosterone; Blood Pressure; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Femal | 2006 |
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
Topics: Aged; Aged, 80 and over; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; D | 1999 |
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi | 2000 |
A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
Topics: Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2000 |
A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chromium Radioisotopes; Cyclooxygenase 2; Cyclooxyge | 2000 |
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2000 |
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2000 |
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2000 |
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2000 |
Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygen | 2001 |
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Disability Evaluation; | 2001 |
Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.
Topics: Aged; Aged, 80 and over; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Lactones; M | 2001 |
Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
Topics: Aged; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; | 2001 |
Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints.
Topics: Analgesics; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Humans | 2001 |
79 other studies available for rofecoxib and Arthritis, Degenerative
| Article | Year |
|---|---|
Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
Topics: Analgesics; Animals; Azepines; Azirines; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Cy | 2013 |
Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, N | 2009 |
Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, N | 2009 |
Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, N | 2009 |
Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, N | 2009 |
Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.
Topics: Celecoxib; Cross-Sectional Studies; Cyclooxygenase Inhibitors; Diuretics; Edema; Humans; Hypertensio | 2002 |
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Myocardi | 2002 |
[No chance for pain. Rofecoxib eases not only tooth extraction].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; La | 2002 |
Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Child; Cost of | 2002 |
Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2002 |
Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cross-Sectional S | 2002 |
[Already the drug of choices in the USA. Coxibe in joint pain].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug Appr | 2002 |
Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibito | 2002 |
A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cycl | 2002 |
COX-2 inhibitors: new drugs for the management of pain and inflammation.
Topics: Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid | 2001 |
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D | 2003 |
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2003 |
Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Databases, Factual; Drug C | 2003 |
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cycloox | 2003 |
A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Costs and Cost Analysis; C | 2003 |
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben | 2003 |
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Canada; Cel | 2003 |
Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Chi- | 2003 |
Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi | 2003 |
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Community Health Services | 2004 |
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inh | 2004 |
Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor.
Topics: Aged; Chronic Disease; Cognition Disorders; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lactones; | 2004 |
Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecox | 2004 |
Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2004 |
Tolerability of rofecoxib versus naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Industry; Gastrointestinal | 2004 |
Tolerability of rofecoxib versus naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Data Interpretation, Statistical | 2004 |
Tolerability of rofecoxib versus naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Data Interpretation, Statistical | 2004 |
Hypertension associated with therapies to treat arthritis and pain.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agent | 2004 |
Relationship between COX-2 specific inhibitors and hypertension.
Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Hum | 2004 |
[Rofecoxib versus non-steroidal anti-inflammatory drugs in arthrosis treatment: cost-effectiveness analysis for Spain].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Costs and Cost Analysis; Humans; Lactones; Models, Economic | 2004 |
Cardiovascular complications of COX2 selective inhibitors cause considerable concern.
Topics: Cardiovascular System; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Hum | 2004 |
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; C | 2005 |
A world without Vioxx: to COX-2 or not to COX-2?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastroi | 2004 |
Arthritis drug raises risk of sudden heart attack.
Topics: Cyclooxygenase 2; Humans; Isoenzymes; Lactones; Membrane Proteins; Myocardial Infarction; Osteoarthr | 2004 |
Lessons on prescribing and drug safety from the withdrawal of rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Protocols; Cyclooxygenase Inhibitors; Drug Evaluat | 2004 |
Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Female; Health | 2005 |
A tale of two coxibs.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis; Product Surveillance, Postma | 2005 |
Vioxx withdrawal--an opportunity to review primary care management for osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Lactones; Osteoarthritis; Primary Health Care; Sulf | 2005 |
Report of specific cardiovascular outcomes of the ADVANTAGE trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastroi | 2005 |
The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Blood Pressure Monitoring, Ambulator | 2005 |
Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Costs and Cost Analysi | 2006 |
Patient empowerment: rofecoxib revisited.
Topics: Aged; Cyclooxygenase Inhibitors; Disclosure; Humans; Lactones; Osteoarthritis; Patient Advocacy; Pat | 2006 |
Possible role for human leukocyte antigen haplotype in rofecoxib-associated acute pancreatitis and cholestatic hepatitis.
Topics: Aged; Cholestasis, Intrahepatic; Cyclooxygenase 2 Inhibitors; Female; Haplotypes; HLA Antigens; Huma | 2006 |
Cardiac risks with COX-2 inhibitors.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Dose-Res | 2007 |
Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dicl | 2007 |
Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists.
Topics: Animals; Calcium; CHO Cells; Cricetinae; Cricetulus; Cyclooxygenase 2 Inhibitors; Excitatory Amino A | 2007 |
Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; | 2008 |
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coh | 2008 |
COX-2 inhibitors.
Topics: Cyclooxygenase Inhibitors; Enzyme Inhibitors; Humans; Lactones; Osteoarthritis; Safety; Sulfones; Un | 1999 |
Rofecoxib for osteoarthritis and pain.
Topics: Analgesics; Cyclooxygenase Inhibitors; Diarrhea; Drug Interactions; Dyspepsia; Edema; Enzyme Inhibit | 1999 |
COX-2 inhibitors. Magic bullets or merely mortal?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
Second selective COX-2 inhibitor receives marketing approval.
Topics: Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 1999 |
The cox-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 1999 |
COX-2 inhibitors.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenas | 2000 |
Selective COX-2 inhibitors.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2001 |
Severe upper gastrointestinal bleeding during treatment with rofecoxib for osteoarthritis.
Topics: Aged; Cyclooxygenase Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Lactones; Osteoarthrit | 2001 |
Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib.
Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Cyclooxygenase Inhibitor | 2001 |
[Therapy of arthrosis. Life threatening gastrointestinal events can be reduced].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 2001 |
Arthritis: what it is, why you get it and how to stop the pain.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Celecoxib; Cyclooxy | 2001 |
[COX-2 inhibitor in arthrosis. Discontinuation before operations not necessary].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2001 |
Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; D | 2001 |
Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygena | 2001 |
Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor.
Topics: Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2001 |
Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Belgium; Cyc | 2001 |
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T | 2002 |
Idiopathic paresthesia reaction associated with rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Hypesthesia; Lactones; Middle Aged; Osteoar | 2002 |
Aseptic meningitis associated with rofecoxib.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carpal Tunn | 2002 |
Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cycloox | 2002 |
Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cycloox | 2002 |
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials | 2001 |
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials, Phase II as Topic; Clinic | 2002 |
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr
Topics: Aged; Arthritis, Rheumatoid; Bias; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2; | 2002 |
Selective COX-2 inhibition.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 1999 |
The different patterns of blood pressure elevation by rofecoxib and nabumetone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Butanones; Circadian Rhythm; Female; Humans | 2002 |
Be sure to ask your doctor about....
Topics: Advertising; Anecdotes as Topic; Anti-Inflammatory Agents, Non-Steroidal; Drug Industry; Drug Prescr | 2002 |
Right ballpark, wrong base: assessing safety of NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pep | 2002 |